Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: Incidence and risk factors

Retina

Volumn 28, Issue 4, 2008, Pages 573-580

  Vasconcelos Santos, Daniel V ^a   Nehemy, Patrícia G ^a,b   Schachat, Andrew P ^c   Nehemy, Márcio B ^a,b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Institute of Vision   (Brazil)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Intravitreal triamcinolone acetonide injection; Ocular hypertension; Risk factors

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CIPROFLOXACIN; DEXAMETHASONE; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CILIARY DISK; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; VITRECTOMY;

ADULT; AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INCIDENCE; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; MIDDLE AGED; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; RISK FACTORS; TONOMETRY, OCULAR; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 42549132257     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31816079e8     Document Type: Article

References (53)

1. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;26:198-205.
2. Bartlett JD, Woolley TW, Adams CM. Identification of high intraocular pressure responders to topical ophthalmic corticosteroids. J Ocul Pharmacol 1993;9:35-45.
3. Bui CM, Chen H, Shyr Y, Joos KM. Discontinuing nasal steroids might lower intraocular pressure in glaucoma. J Allergy Clin Immunol 2005;116:1042-1047.
4. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005;24:587-611.
5. Wingate RJB, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999;27:431-432.
6. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001;29:2-6.
7. Jaissle GB, Szurman P, Bartz-Schmidt KU. Ocular side effects and complications of intravitreal triamcinolone injection. Ophthalmologe 2004;101:121-128.
8. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone. Arch Ophthalmol 2004;122:336-340.
9. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005;40:63-68.
10. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006;141:629-637.
11. Konstantopoulos A, Williams CP, Newsom RS, Luff AJ. Ocular morbidity associated with intravitreal triamcinolone acetonide. Eye 2007;21:317-320.
12. Vasconcelos-Santos DV, Costa LT, Magalhães EP, et al. Efeito da triancinolona intravítrea na pressão intra-ocular. Rev Bras Oftalmol 2005;64:32-36.
13. Conway MD. The problem of pressure elevation associated with intravitreal triamcinolone. Br J Ophthalmol 2006;90:934-935.
14. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-743.
15. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005;19:122-127.
16. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
17. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003.
18. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol 1999;117:1329-1345.
19. SPSS for Windows [computer program], Version 12. Chicago, IL: SPSS, Inc.; 2004.
20. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res 1999;18:629-667.
21. Kubota T, Okabe H, Hisatomi T, et al. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006;15:117-119.
22. Singh IP, Ahmad SI, Yeh D, et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004;138:286-287.
23. Vedantham V. Intraocular pressure rise after intravitreal triamcinolone. Am J Ophthalmol 2005;139:575.
24. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995;120:55-64.
25. Bui Quoc E, Bodaghi B, Adam R, et al. Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis. J Fr Ophtalmol 2002;25:1048-1056.
26. Finamor LP, Dimantas MAP, Campos VE, et al. Efeitos da injeção subtenoniana posterior de corticóide em pacientes com uveíte. Arq Bras Oftalmol 2003;66:289-291.
27. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-250.
28. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-390.
29. Jonas JB, Kreissig I, Degenring RF. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-27.
30. Hayashi K, Hayashi H. Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2005;139:972-982.
31. Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005;112:1916e1-1916e7.
32. Vasconcelos-Santos DV, Magalhães EP, Nehemy MB. IVTA and glaucoma: Brazil report [e-letter]. Br J Ophthalmol; Available at: http://bjo.bmj.com/cgi/ eletters/90/8/999. Accessed September 13, 2006.
33. Avci R, Kaderli B, Akalp FD. Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema. Clin Exp Ophthalmol 2006;34:27-32.
34. Jampol LM, Yannuzzi LA, Weinreb RN. Glaucoma and intravitreal steroids. Ophthalmology 2005;112:1325-1326.
35. Jonas J, Heatley G, Spaide R, Varma R. Intravitreal triamcinolone acetonide and secondary ocular hypertension. J Glaucoma 2005;14:168-171.
36. Agrawal S, Agrawal J, Agrawal TP. Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004;138:679-680.
37. Agrawal S, Agrawal J, Agrawal TP. Management of intractable glaucoma following intravitreal triamcinolone acetonide. Am J Ophthalmol 2005;139:575-576.
38. Agrawal S, Agrawal J, Agrawal TP. Intravitreal triamcinolone and IOP. Ophthalmology 2006;113:159-160.
39. Viola F, Morescalchi F, Staurenghi G. Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch Ophthalmol 2006;124:133-134.
40. Meyer CH, Mennel S, Schmidt JC. Intravitreal triamcinolone acetonide may increase the intraocular pressure even in vitrectomized eyes after more than 3 months. Am J Ophthalmol 2005;140:766-767.
41. Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye. Br J Ophthalmol 2006;90:705-708.
42. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-686.
43. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:560-562.
44. Jonas JB, Degenring RF, Kamppeter BA, et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-160.
45. Chang S. LXII Edward Jackson lecture: open angle glaucoma after vitrectomy. Am J Ophthalmol 2006;141:1033-1043.
46. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-1525.
47. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-645.
48. Lin JM, Tsai YY, Chiu YT, Hung PT. Paracentesis before or after intravitreal injection of triamcinolone acetonide and its necessity? Am J Ophthalmol 2006;141:985-986.
49. Degenring RF, Sauder G. Vitreous prolapse and IOL dislocation during intravitreal injection of triamcinolone acetonide. Graefes Arch Clin Exp Ophthalmol 2005;20:1-2.
50. Dwinger MC, Pieper-Bodeewes I, Eter N, Holz FG. Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection. Klin Monatsbl Augenheilkd 2005;222:638-642.
51. Benz MS, Albini TA, Holz ER, et al. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006;113:1174-1178.
52. Chen SD, Mohammed Q, Bowling B, Patel CK. Vitreous wick syndrome: a potential cause of endophthalmitis after intravitreal injection of triamcinolone through the pars plana. Am J Ophthalmol 2004;137:1159-1160.
53. Friedman DS, Wilson MR, Liebmann JM, et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004;138:S19-S31.